|
|
||||||||
1 Laboratory of Bio-organic Chemistry, College of Pharmacy, Nihon University, Chiba 274-8555, Japan
2 Departments of Microbiology and Infectious Diseases, Toho University School of Medicine, 5-21-16 Ohmorinishi, Ohtaku, Tokyo 143-8540, Japan
3 Suntory Institute for Bioorganic Research, Osaka 618-8503, Japan
4 Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, MI 48109-0360, USA
Correspondence
Kazuhiro Tateda
kazu{at}med.toho-u.ac.jp
Received 4 April 2006
Accepted 21 June 2006
in the immunized mice were significantly lower than those of control mice (P<0.05). Furthermore, the extractable 3-oxo-C12-HSL levels in serum and lung homogenate were also significantly diminished in the immunized mice. Immune serum completely rescued reduction of cell viability by 3-oxo-C12-HSL-mediated apoptosis in macrophages in vitro. These results demonstrated that specific antibody to 3-oxo-C12-HSL plays a protective role in acute P. aeruginosa infection, probably through blocking of host inflammatory responses, without altering lung bacterial burden. The present data identify a promising potential vaccine strategy targeting bacterial quorum-sensing molecules, including autoinducers.
Abbreviations: C4-HSL, N-butanoyl-L-homoserine lactone; HRP, horseradish peroxidase; HSL, homoserine lactone; IL, interleukin; OV, ovalbumin; 3-oxo-C12-HSL, N-3-oxododecanoyl-L-homoserine lactone; TNF, tumour necrosis factor.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | J MED MICROBIOL | MICROBIOLOGY | J GEN VIROL | ALL SGM JOURNALS |